Connect with us

Hi, what are you looking for?

Captain Of Success
Top Stories

Stock Markets

Bird flu vaccine approval could come by Q2

REUTERS

THE Department of Agriculture (DA) said a vaccine for Avian Influenza (AI), or bird flu, could be approved by the Food and Drug Administration (FDA) by the second quarter, following the completion of two field trials.

Agriculture Assistant Secretary and Spokesperson Arnel V. de Mesa said the results of the vaccine trials will be presented by the Bureau of Animal Industry’s (BAI) Veterinary Technical Advisory Committee to the FDA for approval.

“By the end of this quarter, the two trials for the AI vaccine should be done, and then mapadala na sa  (will be sent to the) FDA,” Mr. De Mesa told reporters.

He added that the vaccines currently undergoing trials are from Hungary and Germany.

“Hopefully within the second quarter, there will be action (from the FDA),” he said.

The DA is looking to procure 30 million doses of approved vaccine with funding of P300 million.

Some 53 municipalities across nine provinces remain affected by bird flu, the BAI reported on Jan. 24. — Adrian H. Halili

    You May Also Like

    Stock Markets

    SULA Spirits celebrates Filipino artistry with bottles that are as refined as the craft they hold. Have you ever wondered how the perfect day...

    Finance

    Sara Davies, the Dragons’ Den entrepreneur, is set to regain control of Crafter’s Companion, the craft supply business she founded, through a fast-tracked pre-pack...

    Finance

    Businesses shed jobs at the fastest pace in four years last month after higher employment costs and mounting uncertainty from the autumn budget dented...

    Finance

    Millions of people across the UK are at risk of penalties after HM Revenue & Customs (HMRC) revealed that 5.4 million taxpayers have yet...

    Disclaimer: CaptainOfSuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
    The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.